Bupropion (Zyban®, sustained-release tablets): reported adverse reactions

April 1999
CMAJ: Canadian Medical Association Journal;4/06/99, Vol. 160 Issue 7, p1050
Academic Journal
No abstract available.


Related Articles

  • Bupropion (Zyban, sustained-release tablets): update. Dunlop, Heather // CMAJ: Canadian Medical Association Journal;1/11/2000, Vol. 162 Issue 1, p106 

    Reports adverse drug reactions (ADRs) to bupropion (Zyban, sustained-release tablets), which is used for smoking cessation. Number and type of reactions to Zyban as reported to the Canadian Adverse Drug Reaction Monitoring Program; ADRs, including central and peripheral nervous system,...

  • Antidepressant offers smokers another way to kick butts. O'Brien, Erin // Drug Topics;6/2/97, Vol. 141 Issue 11, p25 

    Introduces Glaxo Wellcome Inc.'s Zyban Sustained-Release Tablets, an over-the-counter drug that works directly on chemicals in the brian that lead to nicotine craving and addiction. Mechanisms of bupropion; Active ingredient of the tablets; Side effects.

  • 'Problem' drugs listed.  // GP: General Practitioner;4/19/2004, p19 

    A list of the Great Britain's 10 most problematic prescribed drugs cites clozapine (Clozaril) as the most likely to cause an adverse reaction. During 2003, the Medicines and Healthcare Products Regulatory Agency received a total of 18,060 suspected adverse reaction reports, nearly a third of...

  • New drug for smokers who want to quit.  // Saturday Night;Apr99, Vol. 114 Issue 3, p83 

    Reports that Health Canada has approved the use of bupropion hydrochloride (Zyban) for smoking cessation. How it is used; Effectiveness of bupropion.

  • Bupropion and seizures.  // WHO Drug Information;2001, Vol. 15 Issue 2, p82 

    Reports that the Singaporean Drug Monitoring Unit has received reports of seizures with bupropion/amfebutamone (Zyban) in recipients who had not consumed alcohol and had no history of seizure disorders. Hospitalization of men aged between 37 and 41 years; Other adverse events reported in...

  • Bupropion update.  // WHO Drug Information;2001, Vol. 15 Issue 2, p76 

    Presents news update pertaining to bupropion (Zyban SR), used as a short-term aid to smoking cessation. Assessment of reactions to bupropion; Possibility that bupropion can cause seizures and is contraindicated in patients with epilepsy.

  • Tolerability and Safety of Sustained-Release Bupropion in the Management of Smoking Cessation. Aubin, H-J. // Drugs;2002 Supplement 2, Vol. 62 Issue 11, p45 

    Sustained-release bupropion (bupropion SR) was first launched in the US in 1997 as an aid to smoking cessation and has since been launched in many other countries. Adverse events associated with the use of bupropion SR at the recommended dosage of 150mg twice daily in clinical trials most...

  • Glaxo launches TV DTC advertising for Zyban.  // Drug Store News;12/13/99, Vol. 21 Issue 20, p49 

    Describes the direct-to-consumer television advertisement launched by Glaxo for Zyban sustained-release tablets as part of a comprehensive program to help smokers ease into quitting. Comments from Sharon Sharo, director of Zyban marketing at Glaxo; What the campaign explains; Features.

  • News in brief….  // Reactions Weekly;8/6/2005, Issue 1063, p5 

    Highlights findings on adverse reaction research as of August 2005. Increased loss of bone mineral density among postmenopausal women who are administered with exemestane; Rise in the urinary ratio of dextromethorpan and dextrorphan in smokers receiving sustained-release bupropion; Association...

  • Zyban.  // Royal Society of Medicine: Medicines;2002, p581 

    This article presents information on Zyban which is a proprietary, non-prescription preparation of the newly introduced drug bupropion, and can be used to alleviate the withdrawal symptoms experienced when giving up smoking tobacco products. It is available as tablets.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics